The earnings call presented a mixed picture. While there were significant achievements in terms of revenue growth, shareholder returns, and strong performance in Evernorth, there were notable challenges in the stop loss segment that impacted overall earnings. The company's proactive measures to address these issues and its strong financial position indicate a balanced outlook.

Company Guidance

During the call, the Cigna Group provided detailed guidance on several financial metrics, reflecting their strategic direction and financial health. For the full-year 2024, Cigna reported a 27% growth in revenue, reaching approximately $247 billion, and adjusted earnings per share (EPS) of $27.33, which marked a 9% increase year-over-year but fell short of expectations. They returned $8.6 billion to shareholders through dividends and share repurchases, with an 8% increase in quarterly dividends to $1.51 per share. Looking ahead to 2025, Cigna anticipates EPS of at least $29.50, driven by revenue projections of $252 billion and adjusted income from operations of $7.9 billion. The company expects to maintain a strong capital position, projecting $10 billion in operating cash flow and planning significant share repurchases, supported by an increased authorization of $10.3 billion. Despite the short-term pressures, particularly in their stop loss products, they remain confident in achieving long-term growth targets of 10% to 14%, leveraging their differentiated capabilities and business portfolio.

Full-Year Revenue Growth

Cigna delivered full-year revenue growth of 27% to approximately $247 billion.

Record Shareholder Returns

The company returned $8.6 billion to shareholders through dividends and share repurchase, with an 8% increase in the quarterly dividend to $1.51 per share.

Strong Performance in Evernorth

Evernorth's specialty and care services segment showed strong results, with adjusted revenues growing 33% to $53.7 billion and pre-tax adjusted earnings growing 14% to $2.1 billion.

Biosimilar Adoption Success

Biosimilar use for eligible Humira scripts reached nearly 50% by year-end 2024, and plans to offer an interchangeable Stelara Biosimilar with $0 cost to patients were announced.

Strong Cash Flow and Capital Deployment

Cigna delivered $10.4 billion of cash flow from operations in 2024 and expects to deliver approximately $10 billion in 2025.

---

Cigna (CI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 02, 2025	2025 (Q1)	6.42 / -	6.47	―	―	―
Jan 30, 2025	2024 (Q4)	7.83 / 6.64	6.79	-2.21% (-0.15)
Oct 31, 2024	2024 (Q3)	7.23 / 7.51	6.77	10.93% (+0.74)
Aug 01, 2024	2024 (Q2)	6.43 / 6.72	6.13	9.62% (+0.59)
May 02, 2024	2024 (Q1)	6.22 / 6.47	5.41	19.59% (+1.06)
Feb 02, 2024	2023 (Q4)	6.54 / 6.79	4.96	36.90% (+1.83)
Nov 02, 2023	2023 (Q3)	6.68 / 6.77	6.04	12.09% (+0.73)
Aug 03, 2023	2023 (Q2)	6.03 / 6.13	6.22	-1.45% (-0.09)
May 05, 2023	2023 (Q1)	5.26 / 5.41	6.01	-9.98% (-0.60)
Feb 03, 2023	2022 (Q4)	4.86 / 4.96	4.77	3.98% (+0.19)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

CI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 30, 2025	$303.31	$282.98	-6.70%
Oct 31, 2024	$311.58	$313.49	+0.61%
Aug 01, 2024	$345.88	$329.94	-4.61%
May 02, 2024	$352.87	$340.34	-3.55%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---